Arkolith/Insider Trading/ESLA/Form 4

Xu Jiandong

Chief Financial OfficerEstrella Immunopharma, Inc. (ESLA) · full profile →Form 4 · filed Feb 14, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 30, 2024Grant(A)491K——491K
Oct 30, 2024Grant(A)509K——509K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-014306) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML